CAMP — Camp4 Therapeutics Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1736730 ·
Last close
$3.45
Market Cap
$179.14M
52W High
$5.25
52W Low
$2.90
ADV30
282,247
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,294,000 | — | -13,071,000 | -18,331,000 | 105,457,000 | 99,209,000 | 74,555,000 |
| Dec 2025 | 348,000 | — | -12,776,000 | -40,284,000 | 117,808,000 | 109,517,000 | 70,104,000 |
| Sep 2025 | 795,000 | — | -13,157,000 | -15,099,000 | 86,395,000 | 75,255,000 | 27,728,000 |
| Jun 2025 | 1,497,000 | — | -13,028,000 | -12,587,000 | 51,275,000 | 39,052,000 | 11,288,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-29,553,000
Investing CF
$-243,000
Financing CF
$75,890,000
CapEx
$-542,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.48
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-292,156,000
Inventory
—
Receivables
$155,000
ST Investments
—
EBIT TTM
$-52,061,000
Pretax Income TTM
$-80,403,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,934,000
EBITDA
$-50,294,000
Free Cash Flow
$-13,805,000
Enterprise Value
$82,057,008
Total Cash
$99,209,000
Total Debt
$2,122,000
Shares Out
51,925,800
Trailing EPS
$-2.35
Book Value
$0.59
ROE
-209.3%
ROA
-38.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,498,000 | -52,061,000 | -80,403,000 | 117,808,000 | 70,104,000 | — | -29,553,000 |
| Dec 2024 | 652,000 | -53,088,000 | -51,791,000 | 78,307,000 | 15,163,000 | — | -45,562,000 |
| Dec 2023 | 350,000 | -51,879,000 | -49,291,000 | 54,946,000 | 178,676,000 | — | -44,155,000 |
| Dec 2022 | 0 | -45,001,000 | -44,192,000 | 102,549,000 | 180,080,000 | — | -38,543,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-13,484,000
OpCashFlow TTM
$0
Assets (Latest)
$78,307,000
Forward EPS
$-0.78
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NBP | NovaBridge Biosciences | $185.04M | $1.60 | — |
| NERV | Minerva Neurosciences, Inc. | $185.42M | $3.98 | — |
| NGEN | NERVGEN PHARMA CORP. | $172.39M | $1.62 | — |
| INDP | Indaptus Therapeutics, Inc. | $171.88M | $1.29 | — |
| IMUX | IMMUNIC, INC. | $190.29M | $13.97 | — |
News headlines (Yahoo Finance, 1h cache)
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
2026-07-27 11:00 · Yahoo
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-17 20:05 · Yahoo
New Strong Sell Stocks for July 16th
2026-07-16 08:32 · Yahoo
Is CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Undervalued Ahead of Key CMP-002 Clinical Development Milestones?
2026-07-02 20:06 · Yahoo
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
2026-07-01 11:00 · Yahoo
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-19 20:05 · Yahoo
Here's Why We're Not Too Worried About Camp4 Therapeutics' (NASDAQ:CAMP) Cash Burn Situation
2026-06-06 12:57 · Yahoo
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
2026-05-14 11:00 · Yahoo
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates
2026-05-07 23:05 · Yahoo
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
2026-05-07 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.